Abstract
Treatment of biofeedback in children and the complex use of drugs, that is, each drug must be pathogenetically justified, taking into account the individual characteristics of the child, and also based on knowledge of the mechanism of their action and pharmacokinetics. It is necessary to have a complex effect on individual links in the pathogenesis of broncho-obstructive syndrome in many cases, which justifies the use of complex drugs with a combined mechanism of action. Thus, the treatment of biofeedback in children is a responsible task for the pediatrician, which consists in the rational selection of drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Medical Genetics and Clinical Biology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
